Drug Trial Radar · NCT05420961
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-experienced Adults (V116-006, STRIDE-6)
Last checked: Nov 19, 2026Latest source record: Oct 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
717
Actual
Start
Jul 12, 2022
Primary completion
May 16, 2023
Study completion May 16, 2023
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Jun 16, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This a study of V116 in adults ≥50 years of age who previously received a pneumococcal vaccination ≥1 year before enrollment. The primary objectives of this study are to evaluate the safety, tolerability, and immunogenicity of V116.
Conditions
- Pneumonia, Pneumococcal
Interventions
V116Biological
Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
PCV15Biological
Pneumococcal 15-valent conjugate vaccine with 2 μg of each of the PnPs antigen: 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F, and 4 μg of 6B in each 0.5 mL sterile suspension
PPSV23Biological
Pneumococcal 23-valent vaccine with 25 μg of each of the PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Solicited Injection-site Adverse Events (AEs)Time frame: Up to 5 days post-vaccination
- Percentage of Participants With Solicited Systemic AEsTime frame: Up to 5 days post-vaccination
- Percentage of Participants With Vaccine-related Serious Adverse Events (SAEs)Time frame: Up to ~180 days
- Geometric Mean Titer (GMT) of Serotype-specific Opsonophagocytic Activity (OPA)Time frame: 30 Days post-vaccination
Locations
51 sites in 9 countries. Site status is shown where the registry gives one.
Central Research Associates ( Site 0024)
Birmingham, Alabama
Lenzmeier Family Medicine/CCT Research ( Site 0008)
Glendale, Arizona
Fiel Family and Sports Medicine, PC/CCT Research ( Site 0006)
Tempe, Arizona
Southland Clinical Research Center ( Site 0026)
Fountain Valley, California
Diablo Clinical Research, Inc. ( Site 0019)
Walnut Creek, California
Alliance for Multispecialty Research, LLC ( Site 0020)
Coral Gables, Florida
Indago Research & Health Center, Inc ( Site 0005)
Hialeah, Florida
Advanced Medical Research Institute ( Site 0018)
Miami, Florida
Solaris Clinical Research ( Site 0025)
Meridian, Idaho
Centennial Medical Group ( Site 0002)
Elkridge, Maryland
Arcturus Healthcare , PLC, Troy Internal Medicine Research Division ( Site 0016)
Troy, Michigan
Meridian Clinical Research, LLC ( Site 0009)
Norfolk, Nebraska
Advanced Medical Research ( Site 0001)
Maumee, Ohio
University of Texas Medical Branch-Sealy Institute for Vaccine Sciences Clinical Trials Program ( Si
Galveston, Texas
Health Research of Hampton Roads, Inc. ( Site 0003)
Newport News, Virginia
Hamilton Medical Research Group ( Site 0114)
Hamilton, Ontario, Canada
Milestone Research Inc. ( Site 0104)
London, Ontario, Canada
Manna Research Mirabel ( Site 0109)
Mirabel, Quebec, Canada
CHU de Québec-Université Laval-Équipe de recherche en vaccination ( Site 0120)
Québec, Quebec, Canada
Diex Recherche Sherbrooke Inc. ( Site 0101)
Sherbrooke, Quebec, Canada
Hopitaux Universitaires Paris Centre-Hopital Cochin ( Site 0203)
Paris, France
CHU Bordeaux Haut-Leveque ( Site 0202)
Pessac, Aquitaine, France
CHRU de Brest ( Site 0200)
Brest, Finistere, France
centre hospitalier lyon sud ( Site 0204)
Pierre-Bénite, Rhone, France
Rambam Health Care Campus ( Site 0303)
Haifa, Israel
Maccabi Health Services - Holon ( Site 0305)
Holon, Israel
Maccabi Healthcare Services ( Site 0306)
Jerusalem, Israel
Hadassah Medical Center-Clinical Reaserch Unit ( Site 0300)
Jerusalem, Israel
Meir Medical Center ( Site 0301)
Kfar Saba, Israel
Sheba Medical Center-Early Phase Clinical Trials Unit ( Site 0304)
Ramat Gan, Israel
Clalit Health Services - Sakhnin Community Clinic-Research Unit ( Site 0302)
Sakhnin, Israel
Azienda Ospedaliero Universitaria Policlinico Riuniti di Foggia ( Site 0405)
Foggia, Italy
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico ( Site 0400)
Milan, Lombardy, Italy
Ospedale San Raffaele ( Site 0403)
Milan, Lombardy, Italy
A.O.U. Policlinico Paolo Giaccone ( Site 0402)
Palermo, Sicily, Italy
PS Clinic ( Site 0700)
Fukuoka, Japan
Nishikumamoto Hospital ( Site 0701)
Kumamoto, Japan
The Catholic University of Korea, Eunpyeong St. Mary's Hospital ( Site 0752)
Seoul, South Korea
The Catholic Univ. of Korea Seoul St. Mary's Hospital ( Site 0753)
Seoul, South Korea
Hallym University Kangnam Sacred Heart Hospital-Internal Medicine ( Site 0754)
Seoul, South Korea
Showing 40 of 51 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.